A Phase 3 interventional study of eptacog alfa (activated) in Acquired Bleeding Disorder and Intracerebral Haemorrhage, sponsored by Novo Nordisk A/S. Completed at 167 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-12.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing recombinant FVIIa in Cerebral Hemorrhage — 1 open to participants now, 2 under way, 2 of them phase 3. recombinant FVIIa · Cerebral Hemorrhage.
Among the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, this one is the 2nd largest by enrollment, is one of 3 that started in 2005, is one of 3 in phase 3, and was the 1st registered.
457 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.
Browse Cerebral Hemorrhage studies →1 of the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage is open now, in 6 countries. Recruiting first, the newest first:
Joseph Broderick, MD · Sites in United States, Canada, Germany and 3 more countries
Ages 18–80
By country, each count listing its studies:
recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 113 Cerebral Hemorrhage studies recruiting now, 59 (52%) set no upper age limit and 9 (8%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2005.
This study's enrollment of 829 is above the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.
Median enrollment 90 across the 11 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 6 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 5 studies filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America.
The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Reducing disability and improving clinical outcome
Time frame: After 3 months
Reducing mortality
Reducing hematoma growth
Showing the first 100 of 167 sites across 23 countries. Choose a country and city above to see the rest.
The record gives a start of May 2005, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant FVIIa